The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: A dose-response study

Journal of Clinical Psychopharmacology

Volumn 18, Issue 1, 1998, Pages 19-25

  Khan, Arifulla ^a   Upton, G Virginia ^b   Rudolph, Richard L ^b   Entsuah, Richard ^b   Leventer, Steven M ^c   Baumel, Barry ^d   Claghorn, James ^e   Cunningham, Lynn ^f   DuBoff, Eugene A ^g   Ferguson, James ^h   Goldstein, David ⁱ   Mattes, Jeffrey Allan ^j   Mendels, Joseph ^k   Post, Gary ^l   Patrick, Roger ^l   Shrivastava, Ram ^m   Weiss, Kenneth ⁿ  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b WYETH AYERST RESEARCH   (United States)

^c IQVIA   (United States)

^d Baumel Eisner Neuromedical Institute   (United States)

^e Clinical Research Associates   (United States)

^f Vine Street Clinical Research Center ^*  (United States)

^g Center for Behavioral Medicine   (United States)

^h Pharmacology Research Corporation   (United States)

ⁱ GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Psycho Pharm Research   (United States)

^k Southern NJ Medical Center   (United States)

^l Denver Drug Research Center   (United States)

^m Eastside Compreh Medical Services   (United States)

ⁿ Delaware Valley Research Associates   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VENLAFAXINE;

ADULT; ANXIETY; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STATISTICAL ANALYSIS; VERTIGO; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DIZZINESS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NAUSEA; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS;

EID: 0031963340     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199802000-00004     Document Type: Article

References (18)

1. Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry 1994;55[suppl A]:6-22.
2. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM. Biochemical, neurophysiological, and behavioral effects of WY-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-9.
3. Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 1994;55[suppl A]:34-41.
4. Mendels J, Johnston R, Mattes J, Riesenberg R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993;29:169-74.
5. Khan A, Fabre LF, Rudolph R. Venlafaxine in depressed outpatients. Psychopharmacol Bull 1991;27:141-1.
6. Schweizer E, Weise C, Clary C, Fox I, Rickels K. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991;11:233-6.
7. Montgomery SA. Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993;54:119-26.
8. Effexor prescribing information. Physicians' desk reference. 50th ed. Montvale, NJ: Medical Economics Company, 1996:2719-23.
9. Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-8.
10. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106.
11. Shrivastava RK, Cohn C, Crowder J, Davidson J, Dunner D, Feighner J, Kiev A, Patrick R. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994;14:322-9.
12. Klamerus KJ, Maloney K, Rudolph R, Sisenwine SF, Jusko WJ, Chiang S. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992;32:716-24.
13. Troy SM, Park VD, Fruncello RJ, Chiang ST. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J Clin Pharmacol 1995;35:404-9.
14. Shrivastava R, Patrick R, Scherer N, Upton GV. A dose-response study of venlafaxine [abstract]. Neuropsychopharmacology 1994;10[3S pt 2]:221S.
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
16. Montgomery SA, Åsberg M. A new depression rating scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
17. Guy W. ECDEU assessment manual for psychopharmacology. Rev. ed. Bethesda, MD: U.S. Dept HEW, National Institute of Mental Health, 1976:217.
18. Rudolph R, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16[suppl 2]:54S-61S.